Physician profile
Manuela Georgescu
NPI 1912157306
$6,913.56
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,170 · 2020: $269 · 2021: $370 · 2022: $1,853 · 2023: $1,132 · 2024: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,404.00 | 2019 | |
| Abbvie INC. | $780.00 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $734.04 | 2019-2023 | Austedo Xr, Austedo, Uzedy |
| Otsuka America Pharmaceutical, INC. | $729.47 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $685.48 | 2019-2020 | |
| Allergan, INC. | $522.30 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $318.91 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $305.47 | 2019-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $267.25 | 2019-2022 | |
| Alkermes, INC. | $259.51 | 2020-2023 | Aristada, Vivitrol, Lybalvi |
| Vanda Pharmaceuticals INC. | $238.77 | 2019-2023 | Hetlioz, Fanapt |
| Lundbeck LLC | $215.17 | 2019-2023 | Rexulti |
| Indivior INC. | $195.75 | 2019-2023 | Perseris |
| Almatica Pharma LLC | $174.85 | 2022-2023 | Venlafaxine, Citalopram, Loreev Xr |
| Ironshore Pharmaceuticals INC. | $36.67 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.63 | 2022 | |
| Tris Pharma INC | $22.29 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuela Georgescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.